Literature DB >> 26363640

Apolipoprotein A1, B levels, and their ratio and the risk of a first stroke: a meta-analysis and case-control study.

Hongli Dong1, Wei Chen2, Xiangyu Wang1, Fuhua Pi3, Yubin Wu4, Shaojie Pang1, Yuqing Xie1, Fangfang Xia1, Qingying Zhang5,6.   

Abstract

The associations of levels of apolipoprotein A1 (ApoA1) and apolipoprotein B and ApoB/A1 ratio and risk of a first stroke have not been reliably documented. We performed a meta-analysis to summarize the relationships and confirmed them in a case-control study. We identified relevant publications in PubMed and Embase databases up to June 1, 2015. A Dersimonian-Laird random effects model was used to compute summary relative risks (RRs) and 95 % confidence intervals (CIs). A case-control study was conducted in a southern Chinese population. We included 8 cohort and 4 case-control studies (222,774 subjects; 10,032 first stroke events) in the meta-analysis. Reduced ApoA1 level and increased ApoB level and ApoB/A1 ratio was associated with a first stroke in cohort studies (RR 0.86 [95 % CI 0.79-0.94], 1.66 [1.62-1.69], and 1.66 [1.63-1.70], respectively) and reduced ApoA1 level and increased ApoB/A1 ratio in case-control studies (0.68 [0.47-0.99] and 1.76 [1.50-2.06], respectively). When stratified by stroke type in cohort studies, the RR for ischemic stroke was 0.83 (0.76-0.90), 1.36 (1.32-1.40), and 1.38 (1.35-1.42) for the 3 factors, respectively. In our case-control study (1013 cases; 1029 controls), the OR for a first ischemic stroke was 0.83 (0.74-0.92), 1.33 (1.18-1.48) and 2.10 (1.76-2.51), respectively, with increased ApoA1 level associated with hemorrhagic stroke (1.37 [1.06-1.78]). Meta-analysis suggests that reduced ApoA1 level and increased ApoB level and ApoB/A1 ratio are risk factors for a first ischemic but not hemorrhagic stroke. Elevated ApoA1 level may be a risk factor for a first hemorrhagic stroke.

Entities:  

Keywords:  Apolipoproteins; Case–control study; Meta-analysis; Risk factor; Stroke

Mesh:

Substances:

Year:  2015        PMID: 26363640     DOI: 10.1007/s11011-015-9732-7

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  30 in total

1.  Apolipoprotein B-to-A1 ratio as a predictor of acute ischemic nonembolic stroke in elderly subjects.

Authors:  Michael S Kostapanos; Leonidas G Christogiannis; Eftychia Bika; Eleni T Bairaktari; John A Goudevenos; Moses S Elisaf; Haralampos J Milionis
Journal:  J Stroke Cerebrovasc Dis       Date:  2010-06-09       Impact factor: 2.136

Review 2.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

3.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.

Authors:  G Walldius; I Jungner; I Holme; A H Aastveit; W Kolar; E Steiner
Journal:  Lancet       Date:  2001-12-15       Impact factor: 79.321

Review 4.  Potential new risk factors for ischemic stroke: what is their potential?

Authors:  Graeme J Hankey
Journal:  Stroke       Date:  2006-06-29       Impact factor: 7.914

5.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies.

Authors:  J Danesh; R Collins; P Appleby; R Peto
Journal:  JAMA       Date:  1998-05-13       Impact factor: 56.272

6.  Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.

Authors:  Martin J O'Donnell; Denis Xavier; Lisheng Liu; Hongye Zhang; Siu Lim Chin; Purnima Rao-Melacini; Sumathy Rangarajan; Shofiqul Islam; Prem Pais; Matthew J McQueen; Charles Mondo; Albertino Damasceno; Patricio Lopez-Jaramillo; Graeme J Hankey; Antonio L Dans; Khalid Yusoff; Thomas Truelsen; Hans-Christoph Diener; Ralph L Sacco; Danuta Ryglewicz; Anna Czlonkowska; Christian Weimar; Xingyu Wang; Salim Yusuf
Journal:  Lancet       Date:  2010-06-17       Impact factor: 79.321

7.  Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study.

Authors:  Florence Canouï-Poitrine; Gerald Luc; Jean-Marie Bard; Jean Ferrieres; John Yarnell; Dominique Arveiler; Pierre Morange; Frank Kee; Alun Evans; Philippe Amouyel; Pierre Ducimetiere; Jean-Philippe Empana
Journal:  Cerebrovasc Dis       Date:  2010-07-23       Impact factor: 2.762

8.  Hypertension, lipoprotein(a), and apolipoprotein A-I as risk factors for stroke in the Chinese.

Authors:  J Woo; E Lau; C W Lam; R Kay; R Teoh; H Y Wong; W Y Prall; L Kreel; M G Nicholls
Journal:  Stroke       Date:  1991-02       Impact factor: 7.914

9.  Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study.

Authors:  G Walldius; A H Aastveit; I Jungner
Journal:  J Intern Med       Date:  2006-03       Impact factor: 8.989

10.  Apolipoprotein B/apolipoprotein A-I ratio and apolipoprotein B: long-term predictors of myocardial infarction in initially healthy middle-aged men--a 13-year follow-up.

Authors:  Caroline Schmidt; Göran Bergström
Journal:  Angiology       Date:  2013-11-25       Impact factor: 3.619

View more
  12 in total

1.  Apolipoproteins B and A1 in Ischemic Stroke Subtypes.

Authors:  Rizwan Kalani; Soumya Krishnamoorthy; D Deepa; Srinivas Gopala; Dorairaj Prabhakaran; David Tirschwell; P N Sylaja
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-02-10       Impact factor: 2.136

2.  Plasma Apolipoproteins A1/B and OxLDL Levels in Patients with Covid-19 As Possible Markers of the Disease.

Authors:  V V Pushkarev; L K Sokolova; S A Chervyakova; Yu B Belchina; O I Kovzun; V M Pushkarev; M D Tronko
Journal:  Cytol Genet       Date:  2021-11-29       Impact factor: 0.579

3.  Association Between Serum Apolipoprotein A1 Levels, Ischemic Stroke Subtypes and Plaque Properties of the Carotid Artery.

Authors:  Ryo Ohtani; Shinsuke Nirengi; Naoki Sakane
Journal:  J Clin Med Res       Date:  2020-08-15

4.  TLR7 rs2897827 Polymorphism Affects TLR7 Gene mRNA Expression and Serum Apolipoprotein A1 Level of Ischemic Stroke Patients in a Chinese Han Population.

Authors:  Lian Gu; Jinying Zhou; Jinjing Tan; Li Su; Qiugui Wei; Haiyun Jiang; Baoyun Liang; Qianli Tang
Journal:  J Mol Neurosci       Date:  2016-07-18       Impact factor: 3.444

5.  Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease.

Authors:  Vasiliki Lygirou; Agnieszka Latosinska; Manousos Makridakis; William Mullen; Christian Delles; Joost P Schanstra; Jerome Zoidakis; Burkert Pieske; Harald Mischak; Antonia Vlahou
Journal:  J Transl Med       Date:  2018-04-17       Impact factor: 5.531

6.  Association analysis of APO gene polymorphisms with ischemic stroke risk: a case-control study in a Chinese Han population.

Authors:  Rongjun Xiao; Shuaiqi Sun; Jiayi Zhang; Yongri Ouyang; Ning Zhang; Min Yang; Tianbo Jin; Ying Xia
Journal:  Oncotarget       Date:  2017-02-20

Review 7.  Neuroprotective Properties of Linagliptin: Focus on Biochemical Mechanisms in Cerebral Ischemia, Vascular Dysfunction and Certain Neurodegenerative Diseases.

Authors:  Michał Wiciński; Karol Górski; Maciej Walczak; Eryk Wódkiewicz; Maciej Słupski; Katarzyna Pawlak-Osińska; Bartosz Malinowski
Journal:  Int J Mol Sci       Date:  2019-08-20       Impact factor: 5.923

8.  The correlation between serum apolipoprotein B/apolipoprotein A1 ratio and brain necrosis in patients underwent radiotherapy for nasopharyngeal carcinoma.

Authors:  Honghong Li; Dong Zheng; Fukang Xie; Xiaolong Huang; Xiaohuang Zhuo; Jinpeng Lin; Yi Li; Yamei Tang
Journal:  Brain Behav       Date:  2020-02-03       Impact factor: 2.708

Review 9.  Search for Reliable Circulating Biomarkers to Predict Carotid Plaque Vulnerability.

Authors:  Núria Puig; Elena Jiménez-Xarrié; Pol Camps-Renom; Sonia Benitez
Journal:  Int J Mol Sci       Date:  2020-11-03       Impact factor: 5.923

10.  Circulating Lipoprotein Lipids, Apolipoproteins and Ischemic Stroke.

Authors:  Shuai Yuan; Bowen Tang; Jie Zheng; Susanna C Larsson
Journal:  Ann Neurol       Date:  2020-10-10       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.